Informations générales (source: ClinicalTrials.gov)

NCT01375400 Statut inconnu
Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event. (Aspirin)
Interventional
  • Ischémie
N/A
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
décembre 2010
29 juin 2024
Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event. The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences. Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Hopital central - 54035 - Nancy - France Sébastien Richard, MD En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Adult men and women

- Ischemic stroke less than 48 hours

- Signed consent


- Danger to prescription of aspirin (haemorrhagic risk...)

- Prescription of heparin or VKA